Evaluation of the Effectiveness of the Selected Method of Treatment of Primary Burning Mouth Syndrome
Sponsored by Wroclaw Medical University
About this trial
Last updated 4 years ago
Study ID
Kb668/2018
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18+ Years
All
Trial Timing
Ended 5 years ago
What is this trial about?
The burning mouth syndrome (BMS) is a chronic pain syndrome of the oral mucosa. Feels
like experiencing a burning sensation, pain, stinging, or numbness in the mouth along
with a feeling of dryness, paraesthesia, taste disturbance or hypersensitivity.The
complaints are usually bilateral, of moderate intensity, they persist for a minimum of
4-6 months and concern the clinically unchanged membrane mucous.The psychiatric aspect of
BMS is very important. The presence of BMS has been shown to be associated with
depression, increased anxiety levels, hypochondria, and carcinophobia and emotional
instability
What are the participation requirements?
Inclusion Criteria
- History of BMS for at least 6 months
- no clinical changes in the oral cavity that are clinically verifiable and may affect symptoms,
- no previous BMS therapy
- age over 18
Exclusion Criteria
- V and VII nerve neuralgia
- patients with uncontrolled diabetes mellitus,
- thyroid disease, anemia,
- Sjogren's disease and
- connective tissue disease (fibromyalgia),
- patients after prior surgical / neurosurgical treatment of the head,
- oncological treatment (radiotherapy),
- pregnant women,
- the occurrence of clinical pathologies in the oral cavity that may cause pain,
- deficiencies of vitamin B12, folic acid